ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)
Vitamin D status and cardiovascular risk in a cohort of acromegalic patients
Iustin-Daniel Toma 1,2 , Raluca Trifanescu 1,2 , Maria-Alexandra Mohora 2 , Ionela Baciu 1,2 , Nicoleta Baculescu 1,2 , Iulia Florentina Burcea 1,2 , Cristina Capatina 1,2 , Roxana Dusceac 2 , Găloiu Simona Andreea 1,2 , Dan Alexandru Niculescu 1,2 , Ileana Nitu 3 , Serban Radian 1,2 & Catalina Poiana 1,2
1Carol Davila University of Medicine and Pharmacy, Endocrinology, Bucharest, Romania; 2C. I. Parhon National Institute of Endocrinology, Pituitary and Neuroendocrine Disorders, Bucharest, Romania; 3C. I. Parhon National Institute of Endocrinology, Cardiology, Bucharest, Romania
Background: Vitamin D deficiency is the most common nutritional deficiency, estimated to affect almost one billion people worldwide. Multiple factors influence 25(OH)D levels: nutrition, sunlight exposure, outdoor physical activity, skin color. Patients with active acromegaly (AA) have lower 25(OH)D levels compared with healthy population and are at a higher risk to develop vitamin D deficiency. Also, some studies have suggested a possible protective role of vitamin D on the cardiovascular system.
Aim: To assess the impact of vitamin D deficiency on cardiovascular disease risk (CVD) in patients with acromegaly from Romania, a country situated in northern hemisphere at latitudes greater than 40°N.
Methods: Retrospective study by analyzing the files of patients with confirmed acromegaly who underwent treatment in a tertiary endocrine center. 134 patients (91F/43M) were included. IGF1, GH, 25(OH)VitaminD were measured by chemiluminescence either at diagnosis of acromegaly or throughout the follow-up. Total, LDL ad HDL cholesterol, triglycerides, serum glucose, HbA1c, blood pressure were also measured and the acromegaly activity was assessed according to the newest guidelines. The ACM patients were divided into three subgroups: active acromegaly (AA), controlled acromegaly (CA) and cured acromegaly. The cardiovascular disease (CVD) risk has been assessed at the moment of vitamin D dosage using European’s Society of Cardiology (ESC) CVD risk tool.
Results: Globally, 95 patients had AA, 30 patients-CA, 3 patients were cured, whilst for 6 patients there was not enough information to quantify their acromegaly status. Mean age at vitamin D dosage was 51.3±12.4 years. AA patients had more frequently normal total cholesterol and triglycerides values if their 25(OH)D was over 20 ng/ml (P=0.008 respectively P=0.05; chi-sq). AA women also had more frequently normal cholesterol values if their 25(OH)D levels were > 20 ng/ml (P=0.01; chi-sq). No differences were found between vitamin D and lipid profile in the other 2 subgroups, regardless of gender. However, after excluding diabetic acromegalic patients, when calculating the personal risk profile for each AA patient (N=53, F+M) using ESC CVD Risk tool and classifying them into low, moderate and severe risk according to age, subjects with 25(OH)D<20 ng/ml levels had more frequent a moderate and severe 10-year CVD episode risk (P=0.03; chi-sq).
Conclusion: Patients with active acromegaly may benefit from dosing the 25(OH)D levels and, if needed, prescribing supplementation may help. Therefore, further prospective studies evaluating the impact of vitamin D levels on CVD risk are necessary to confirm these findings definitively.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more